Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Announces Q2 2024 Financial Results and Business Update
Summary
Crinetics Pharmaceuticals, Inc. reported its financial results for Q2 2024, showing an increase in research and development expenses and general and administrative expenses, leading to a net loss of $74.1 million. The company reported revenues of $0.4 million, derived from the paltusotine licensing arrangement with Sanwa Kagaku Kenkyusho. Crinetics also announced positive initial results from atumelnant studies and presented data from its paltusotine development program at ENDO 2024. Additionally, Marc Wilson, CFO, notified the company of his intention to step down from his position for personal reasons.
Profitelligence Alerts
Get alerts for CRNX
Be first to know when Crinetics Pharmaceuticals Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Official SEC Documents
Advertisement